Compare Eli Lilly And Co (LLY) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Palantir Technologies Inc — how do they compare? Eli Lilly And Co trades at $1,161.67 (market cap $1.02T), while Palantir Technologies Inc trades at $134.57 (market cap $323.28B). The key difference: Eli Lilly And Co is far larger — about 3.2× Palantir Technologies Inc's market cap, and Eli Lilly And Co pays a 0.6% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| LLY | PLTR | |
|---|---|---|
Market Cap | $1.02T | $323.28B |
Sector | Health | Technology |
52-Week High | $1.24K | $207.18 |
52-Week Low | $625.65 | $107.27 |
Enterprise Value | $1.06T | $315.46B |
Dividend Yield | 0.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
Palantir (PLTR) trades at $135.63, up 2.46% today, showing strong momentum despite being 35% below its 52-week high. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company demonstrates exceptional growth with 2025 revenue of $4.48 billion and net income of $1.63 billion, though valuation metrics remain elevated with a P/E of 148.74 and P/S of 65.12. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.33 surpassing the $0.2774 forecast.
Palantir's AI software leadership and accelerating revenue growth present compelling long-term potential, but the premium valuation creates significant risk if growth moderates. Analyst consensus leans bullish with a $185.75 price target, though the stock faces headwinds from competitive pressures and market rotation out of high-multiple software names. The company's strong government contracts and commercial expansion provide stability, but investors should weigh rich multiples against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
